Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.

News

A tumoroid, colon cancer cells grown in 3D

Immunotherapy success could be predicted with new biomarkers

20 January 2026

The deletion of two cancer genes, CHD1 and MAP3K7, improves how well tumours respond to cancer immunotherapy and could be used as biomarkers to help predict which patients are most likely to benefit from treatment, new research shows.

Researchers at the Wellcome Sanger Institute, Open Targets, Netherlands Cancer Institute and their collaborators used a powerful gene-editing tool called CRISPR in a novel approach that cultured tumour cells together with immune cells from the same in...

Read more

Read more news about Open Targets

Our Principles

A systematic approach

Systematically identify and prioritise the best targets to safely and effectively treat rare and common diseases

Our scientific approach
Open Exchange of Ideas

We are committed to making our data, methods and results publicly available as soon as possible to foster an open exchange of ideas

Our latest publications
Multidisciplinary collaboration

We believe in non-exclusive partnerships that foster the free exchange of ideas, expertise, and data

Our partners and collaborators

Blog

Bluesky